Intelligent Bio Solutions expects sixth U.S. patent for fingerprint drug testing technology

INTELLIGENT BIO SOLUTIONS INC.

Expected patent will protect lateral flow technology core to its drug screening system.
Patent strengthens IP portfolio as company plans U.S. market entry in 2025.
CEO Harry Simeonidis states protection is critical for scaling U.S. footprint.
Recent FDA 510(k) submission supports non-invasive sweat-based testing approach.
INBS provides non-invasive alternative to traditional drug screening methods.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.